γδ T cells: Major advances in basic and clinical research in tumor immunotherapy.
10.1097/CM9.0000000000002781
- VernacularTitle:γδ T cells: Major advances in basic and clinical research in tumor immunotherapy
- Author:
Yueqi ZHAO
1
;
Peng DONG
2
;
Wei HE
1
;
Jianmin ZHANG
1
;
Hui CHEN
1
Author Information
1. Department of Immunology, CAMS Key Laboratory for T Cell and Immunotherapy, State Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and School of Basic Medicine, Peking Union Medical College, Beijing 100005, China.
2. Changzhou Xitaihu Institute for Frontier Technology of Cell Therapy, Changzhou, Jiangsu 213000, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Receptors, Antigen, T-Cell, gamma-delta;
Immunotherapy, Adoptive;
T-Lymphocytes;
Immunotherapy;
Neoplasms/therapy*
- From:
Chinese Medical Journal
2024;137(1):21-33
- CountryChina
- Language:English
-
Abstract:
γδ T cells are a kind of innate immune T cell. They have not attracted sufficient attention because they account for only a small proportion of all immune cells, and many basic factors related to these cells remain unclear. However, in recent years, with the rapid development of tumor immunotherapy, γδ T cells have attracted increasing attention because of their ability to exert cytotoxic effects on most tumor cells without major histocompatibility complex (MHC) restriction. An increasing number of basic studies have focused on the development, antigen recognition, activation, and antitumor immune response of γδ T cells. Additionally, γδ T cell-based immunotherapeutic strategies are being developed, and the number of clinical trials investigating such strategies is increasing. This review mainly summarizes the progress of basic research and the clinical application of γδ T cells in tumor immunotherapy to provide a theoretical basis for further the development of γδ T cell-based strategies in the future.
